Abstract:For a selected group of end-stage heart failure (HF) patients, heart transplantation (HTx) remains the last available treatment option. 1 Here, acute transplant rejection represents a pivotal cause of impaired long-term outcomes. Within the first year after HTx, up to 40% of the patients develop an acute cellular rejection (ACR). 2 Despite the potentially fatal impact of an ACR, there is sparse knowledge about the prevalence and role of cardiac autoantibodies (aABs) in this process. Mechanistically, cardiac damage and cardiomyocyte cell death might cause a presentation of former unknown cellular antigens to the immune system, stimulating the production of cardiac aABs. In other circumstances, such as dilated cardiomyopathy (DCM) or ischemic cardiomyopathy (ICM), cardiac aABs against beta-1-adrenergic receptor (β-1AR) or troponin I (TnI) were shown to be associated with cardiac dysfunction and progressive HF. 3 , 4 In animal models, experimental immunization using peptide sequences of cardiac autoantigens is known to cause experimental autoimmune myocarditis (EAM) accompanied by HF and DCM phenotype within susceptible mouse strains. 5-8 Recent studies could identify certain immunogenic peptide sequences in common autoantigens such as TnI or cardiac myosin (CM), causing autoimmunity in animal models after immunization or exposition to the immune system. 8-11 Additionally, current evidence suggests a worse prognosis in HTx recipients with the presence of cardiac aAB. 12 However, accounting for the immunosuppression for prevention of fatal rejection, HTx patients represent a unique study population for detection of cardiac aABs. Current literature describes both, aAB directed against cardiac autoantigens of the vascular endothelium such as endothelin-1 type A receptor or vimentin, as well as aABs against structural cardiac proteins such as CM or lamin A/C. 12-14 Albeit, the knowledge about cardiac aAB in HTx recipients during ACR directed against structural proteins remains scarce and their potential impact is not yet elucidated. 12-17 Thus, this study aimed (1) to serve as a feasibility analysis for a screening of cardiac aABs directed against structural proteins in HTx patients using a peptide array approach and (2) to serve as hypothesis-generating approach for evidence of differently regulated cardiac aABs during ACR in HTx patients (ACR-HTx) compared with non-ACR-HTx.

Outcome-Based Risk Assessment of Non-HLA Antibodies in Heart Transplantation: A Systematic Review

Clinical Prediction Model for Antibody-Mediated Rejection: A Strategy to Minimize Surveillance Endomyocardial Biopsies After Heart Transplantation

Pre-transplant Serum Concentrations of Anti-Endothelial Cell Antibody in Panel Reactive Antibody Negative Renal Recipients and Its Impact on Acute Rejection

Blood-based immunological monitoring after heart transplant. Current status and future prospects

Impact of Alloantibody Strength in Crossmatch Negative DSA Positive Kidney Transplantation

A gentler approach to monitor for heart transplant rejection

Benefit And Risk Of Endomyocardial Biopsy For Heart Transplant Patients In The Contemporary Era

Clinical Outcomes After a Biopsy Diagnosis of Antibody-mediated Rejection in Pediatric Heart Transplant Recipients

Association of non-HLA antibodies against endothelial targets and donor-specific HLA antibodies with antibody-mediated rejection and graft function in pediatric kidney transplant recipients

Redefining Cardiac Antibody-Mediated Rejection With Donor-Specific Antibodies and Graft Dysfunction

Issues of Immunological and Hemodynamic Monitoring Before and During Kidney Transplantation in Sensitized Heart Transplant Recipient

Donor-Specific Antibody Testing is an Effective Surveillance Strategy for High-Risk Antibody Mediated Rejection in Heart Transplant Patients in the Contemporary Era

Heart Transplant Rejection: From the Endomyocardial Biopsy to Gene Expression Profiling

Preliminary Investigation of the Biomarkers of Acute Renal Transplant Rejection Using Integrated Proteomics Studies, Gene Expression Omnibus Datasets, and RNA Sequencing.

Predictive Efficacy of the Index of Microcirculatory Resistance for Acute Allograft Rejection and Cardiac Events After Heart Transplantation: A Systematic Review and Meta-Analysis

Increase of Cardiac Autoantibodies Against Beta-2-adrenergic Receptor During Acute Cellular Heart Transplant Rejection

Unraveling complexity of antibody-mediated rejections, the mandatory way towards an accurate diagnosis and a personalized treatment

Histopathological Characteristics of Percutaneous Endomyocardial Biopsy in Heart Transplant Rejection Surveillance: A Single Center Experience

Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation

Relationship between blood and tissue-based rejection-related transcripts in heart transplantation

Antibody-Mediated Rejection in Kidney Transplantation: A Review